 This study aims to determine the ability of bosentan to reduce high blood pressure in the lungs pulmonary hypertension in patients with scarring fibrosing lung disease. It is a placebo-controlled double blinded study for 16 weeks and it is proposed to follow patients in a 16 week open-label phase with bosentan therapy. 